Nielsen Kirk G.'s Form 4 filing
SpyGlass Pharma, Inc. (SGP) · filed Feb 10, 2026
- Accession no.
- 0001193125-26-045028
- Filed
- Feb 10, 2026, 6:08 PM ET
- Trade date
- Feb 9, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market purchases total $2.64M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nielsen Kirk G.CIK 0001523522 | 10% Owner |
| Klein Peter JustinCIK 0001608710 | 10% Owner |
| Vensana Capital I, L.P.CIK 0001757539 | 10% Owner |
| Vensana Capital I GP, LLCCIK 0001854073 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | Common Stock | CConversionAcquired | +1,690,230 | –F1 | – | 1,690,230 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | CConversionAcquired | +548,067 | –F1 | – | 2,238,297 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | CConversionAcquired | +548,067 | –F1 | – | 2,786,364 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | CConversionAcquired | +359,255 | –F1 | – | 3,145,619 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | PPurchaseAcquired | +165,000 | $16.00 | +$2,640,000 | 3,310,619 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | Common Stock | CConversionDisposed | −1,690,230 | –F1 | – | 0 | Indirect | |
| Feb 9, 2026 | Common Stock | CConversionDisposed | −548,067 | –F1 | – | 0 | Indirect | |
| Feb 9, 2026 | Common Stock | CConversionDisposed | −548,067 | –F1 | – | 0 | Indirect | |
| Feb 9, 2026 | Common Stock | CConversionDisposed | −359,255 | –F1 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
Referenced by the price of 4 transactions in Table I and 4 transactions in Table II.